Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| Forbes Alexandria | PRESIDENT & CEO | 2026-08-18 | 62,000 | $859,320 |
Position changes disclosed in SEC Form 13F filings. These report a quarterly snapshot, not exact trade dates.
| Fund | Change | Quarter |
|---|---|---|
| Sanofi | Sanofi increased this position by 70% ($96,972,009 -> $164,791,427). | 2026-06-30 |
| JOHNSON & JOHNSON | JOHNSON & JOHNSON increased this position by 56% ($57,511,614 -> $89,720,775). | 2026-06-30 |
| PERCEPTIVE ADVISORS LLC | PERCEPTIVE ADVISORS LLC increased this position by 63% ($89,312,864 -> $145,727,749). | 2026-06-30 |
| Rubric Capital Management LP | Rubric Capital Management LP increased this position by 103% ($60,620,000 -> $122,941,000). | 2026-06-30 |
| Opaleye Management Inc. | Opaleye Management Inc. increased this position by 161% ($18,387,423 -> $47,960,500). | 2026-06-30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADAGE CAPITAL PARTNERS GP, L.L.C. increased this position by 72% ($34,640,000 -> $59,444,000). | 2026-06-30 |
| Prosight Management, LP | Prosight Management, LP reduced this position by 95% ($22,775,549 -> $1,215,900). | 2026-06-30 |
| Woodline Partners LP | Woodline Partners LP increased this position by 679% ($2,600,797 -> $20,266,824). | 2026-06-30 |
Largest reported positions as of 2026-06-30.
| Fund | Value | Shares |
|---|---|---|
| Sanofi | $164,791,427 | 12,197,737 |
| PERCEPTIVE ADVISORS LLC | $145,727,749 | 10,786,658 |
| Rubric Capital Management LP | $122,941,000 | 9,100,000 |
| JOHNSON & JOHNSON | $89,720,775 | 6,641,064 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $59,444,000 | 4,400,000 |
| Opaleye Management Inc. | $47,960,500 | 3,550,000 |
| MILLENNIUM MANAGEMENT LLC | $40,148,370 | 2,971,752 |
| 683 Capital Management, LLC | $31,073,000 | 2,300,000 |
| Woodline Partners LP | $20,266,824 | 1,500,135 |
| Knoll Capital Management, LLC | $16,887,500 | 1,250,000 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
This page tracks Sanofi’s institutional portfolio activity as disclosed in its quarterly Form 13F filings with the SEC. Rather than a one-off news snapshot, think of it as a running ledger — new positions, exits, and size changes get logged here every quarter so you can see how the company’s biotech and pharma stakes shift … Read more